Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial.
High risk of MS in Iranian immigrants in Gothenburg, Sweden.
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study.
Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features.
Noninvasive molecular imaging of neuroinflammation.
Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis.
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
MP2RAGE Multiple Sclerosis Magnetic Resonance Imaging at 3 T.
PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.
Solodyn
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
The mammalian Na+/H+ exchanger gene family--initial structure/function studies.
Brain parenchymal damage in neuromyelitis optica spectrum disorder - A multimodal MRI study.
Psoriasis during natalizumab treatment for multiple sclerosis.
Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator.
Assessment of cerebral venous return by a novel plethysmography method.
Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis.
The impact of environmental infections (parasites) on MS activity.
Characterization of human platelet binding of recombinant T cell receptor ligand.
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
Birth outcomes of pregnancies fathered by men with multiple sclerosis.
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Momenta Pharmaceuticals Announces Launch of Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg

Pages